The introduction of unlabeled ATN-291 as a “blocking” dose reduced the tumor uptake of 89Zr-Df-ATN-29 at all time points examined (p < 0.01) – the uptake was 3.0 ± 0.8, 5.8 ± 1.1, 7.6 ± 0.8, and 9.9 ± 1.2%ID/g at 2, 24, 72, and 120 h p.i., respectively (Figure 2B, 2C and 2D, Table 1). This evidence concerns the gene TYR and neoplasm.